Geneos Wealth Management’s BlueLinx BXC Stock Holding History

Geneos Wealth Management’s Portfolio BXC Stock Details BXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14	Closed	-$1.05K	–	3127
2025 Q1	$1.05K	Buy	+14	New	+$1.3K	﹤0.01%	3046

Other funds holding BXC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JCP

JB Capital Partners Armonk, New York $581M AUM 46.16% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geneos Wealth Management's BXC Position: Q2 2025 in Review

Geneos Wealth Management sold out of BlueLinx (BXC) in Q2 2025, closing a stake of 14 shares — an estimated $1.05K sold.

Geneos Wealth Management first reported a position in BXC in Q1 2025 and held it in 1 quarter. The position peaked at $1.05K in Q1 2025. 144 funds tracked by Wall St. Rank hold BXC as of Q2 2025.

Geneos Wealth Management reported no remaining BlueLinx position as of Q2 2025 after selling out during the quarter.
Geneos Wealth Management sold 14 BlueLinx shares in Q2 2025, an estimated $1.05K.
Geneos Wealth Management first reported a position in BlueLinx in Q1 2025 and held it in 1 quarter.
Geneos Wealth Management's BlueLinx position peaked at $1.05K in Q1 2025.
144 funds tracked by Wall St. Rank held BlueLinx as of Q2 2025.

Based on Geneos Wealth Management's 13F filing for Q2 2025, filed 18 Aug 2025.